• Earlier in May 2026, Relay Therapeutics completed a US$275,000,004 follow-on equity offering at US$12 per share after releasing initial Phase 2 ReInspire data showing zovegalisib achieved a 60% volumetric response rate and broad symptom improvement in PIK3CA‑driven vascular anomalies with a safety profile supportive of chronic dosing.
• An interesting angle is that zovegalisib is being advanced simultaneously in rare vascular anomalies and in an ongoing Phase 3 program for metastatic breast cancer, highlighting Relay’s attempt to leverage one PI3Kα mutant‑selective inhibitor across both genetic disease and oncology indications.
• We’ll explore how these early zovegalisib efficacy signals in PIK3CA‑driven vascular anomalies reshape Relay Therapeutics’ investment narrative around pipeline breadth.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Relay Therapeutics' Investment Narrative?

To own Relay Therapeutics, you have to buy into a high-risk, high-spend biotech story where zovegalisib sits at the center of both the oncology and rare disease pipelines. The fresh Phase 2 ReInspire vascular anomaly data, coupled with the US$275,000,004 equity raise at US$12 per share, looks material for the near term: it shores up the balance sheet ahead of the costly Phase 3 metastatic breast cancer program and strengthens the case that Relay can stretch one PI3Kα mutant selective inhibitor across multiple indications. Near term, the most important catalysts now cluster around further zovegalisib readouts and clarity on any regulatory path in vascular anomalies, while the key risks remain persistent losses, future dilution (especially with a proposed increase in authorized shares) and the binary nature of late stage trial outcomes.

However, investors should also weigh how the enlarged share count and ongoing cash burn affect their exposure. In light of our recent valuation report, it seems possible that Relay Therapeutics is trading beyond its estimated value.

Exploring Other Perspectives

The single Simply Wall St Community fair value estimate clusters at about US$23.67, well above recent trading, but you are seeing that against a company still burning over US$270 million a year and relying on trial data and capital markets cooperation to keep the story moving.

Explore another fair value estimate on Relay Therapeutics - why the stock might be worth as much as 73% more than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Relay Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Relay Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Relay Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 53 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.